CNS Pharmaceuticals annual debt-to-assets ratio
2018
2019
2020
2022
2023
2024
2025
CNS Pharmaceuticals Debt-to-Assets Ratio Growth & History (CNSP)
CNS Pharmaceuticals's debt-to-assets ratio was 0.04 for fiscal 2025.
View full CNS Pharmaceuticals company overviewCNS Pharmaceuticals annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.04 | 0.00 | +1.68% |
| 2024 | 2024-12-31 | 0.04 | −0.14 | −78.81% |
| 2023 | 2023-12-31 | 0.18 | 0.15 | +463.10% |
| 2022 | 2022-12-31 | 0.03 | — | — |
| 2020 | 2020-12-31 | 0.03 | 0.03 | — |
| 2019 | 2019-12-31 | 0.00 | −0.41 | — |
| 2018 | 2018-12-31 | 0.41 | — | — |
CNS Pharmaceuticals quarterly debt-to-assets ratio
Q4.18
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | 0.05 | 0.03 | +225.89% |
| Q4 2025 | 2025-12-31 | 0.04 | — | — |
| Q3 2025 | 2025-09-30 | 0.00 | — | — |
| Q2 2025 | 2025-06-30 | 0.01 | — | — |
| Q1 2025 | 2025-03-31 | 0.02 | — | — |
| Q4 2020 | 2020-12-31 | 0.03 | 0.03 | — |
| Q3 2020 | 2020-09-30 | 0.00 | −0.21 | — |
| Q2 2020 | 2020-06-30 | 0.00 | — | — |
| Q1 2020 | 2020-03-31 | 0.00 | — | — |
| Q4 2019 | 2019-12-31 | 0.00 | −0.41 | — |
| Q3 2019 | 2019-09-30 | 0.21 | — | — |
| Q4 2018 | 2018-12-31 | 0.41 | — | — |
CNS Pharmaceuticals debt-to-assets ratio trends
Over the last five fiscal years, CNS Pharmaceuticals's debt-to-assets ratio increased from 0.03 to 0.04, a change of 0.01. The latest reported quarter, Q1 2026, shows 0.05.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNS Pharmaceuticals source filings ↗